Skip to content
MedsAcross

Molecule

Furosemide

Loop Diuretic
Available on requestCardiology
Presentations
21
Brands
3
Manufacturers
3
Available from stock
0

Furosemide is a loop diuretic indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. MedsAcross supplies Furosemide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Loop Diuretic, Increased Diuresis at Loop of Henle
ATC classification
C03CA01 Furosemide · Sulfonamide drug
US FDA first approval
1 July 1966
EU status
Authorised
Orphan designation
No
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Oral, Intravenous, Intramuscular, Subcutaneous
Dosage forms
Tablet, Injection, Oral solution
Identifiers
UNII 7LXU5N7ZO5RxCUI 4603CAS 54-31-9DrugBank DB00695Q388801

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Edema LASIX is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. LASIX is particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral LASIX may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with LASIX alone.

Source: US FDA prescribing information

Dosing overview

Edema Therapy should be individualized according to patient response to gain maximal therapeutic response and to determine the minimal dose needed to maintain that response. Adults -- The usual initial dose of LASIX is 20 mg to 80mg given as a single dose. Ordinarily a prompt diuresis ensues. If needed, the same dose can be administered 6 to 8 hours later or the dose may be increased. The dose may be raised by 20 mg or 40mg and given not sooner than 6 to 8 hours after the previous dose until the desired diuretic effect has been obtained. The individually determined single dose should then be given once or twice daily (e.g., at 8 am and 2 pm). The dose of LASIX may be carefully titrated up to 600 mg/day in patients with clinically severe edematous states. Edema may be most efficiently and safely mobilized by giving LASIX on 2 to 4 consecutive days each week.

Source: US FDA prescribing information

Contraindications

LASIX is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide.

Source: US FDA prescribing information

Warnings and precautions

Boxed warning (lasix ®): (furosemide) is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient’s needs ( s ee DOSAGE AND ADMINISTRATION ). WARNINGS In patients with hepatic cirrhosis and ascites, LASIX therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma, therefore, strict observation is necessary during the period of diuresis. Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing hypokalemia and metabolic alkalosis.

Source: US FDA prescribing information

Side effects

Adverse reactions are categorized below by organ system and listed by decreasing severity. Gastrointestinal System Reactions 1. hepatic encephalopathy in patients with hepatocellular insufficiency 6. oral and gastric irritation 7. cramping 2. pancreatitis 8. diarrhea 3. jaundice (intrahepatic cholestatic jaundice) 9. constipation 4. increased liver enzymes 10. nausea 5. anorexia 11. vomiting Systemic Hypersensitivity Reactions 1.

Source: US FDA prescribing information

Interactions

LASIX may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function. Except in life-threatening situations, avoid this combination. LASIX should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity. Patients receiving high doses of salicylates concomitantly with LASIX, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites. There is a risk of ototoxic effects if cisplatin and LASIX are given concomitantly. In addition, nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if LASIX is not given in lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

21 presentations of Furosemide, sorted by availability.

MedicineManufacturerRegisterAvailability
Furosemide 20 mg tabletOralGeneric name—US FDAAvailable on request
Furosemide 40 mg tabletOralGeneric name—US FDAAvailable on request
Furosemide 80 mg tabletOralGeneric name—US FDAAvailable on request
Furosemide 20 mg/2 mL injectionIntramuscular, intravenousGeneric name—US FDAAvailable on request
Furosemide 40 mg/4 mL injectionIntramuscular, intravenousGeneric name—US FDAAvailable on request
Furosemide 40 mg/4 mL injectionIntravenousGeneric name—US FDAAvailable on request
Furosemide 100 mg/10 mL injectionIntramuscular, intravenousGeneric name—US FDAAvailable on request
Furosemide 100 mg/10 mL injectionIntravenousGeneric name—US FDAAvailable on request
Furosemide 20 mg/2 mL injectionIntravenousGeneric name—US FDAAvailable on request
Furosemide 10 mg/mL oral solutionOralGeneric name—US FDAAvailable on request
Furosemide 40 mg/5 mL oral solutionOralGeneric name—US FDAAvailable on request
Lasix 40 mg tabletOralValidus PharmaceuticalsUS FDAAvailable on request
Furosemide 10 mg/1 mL injectionIntramuscular, intravenousGeneric name—US FDAAvailable on request
Lasix 20 mg tabletOralValidus PharmaceuticalsUS FDAAvailable on request
Lasix 80 mg tabletOralValidus PharmaceuticalsUS FDAAvailable on request
Lasix Onyu 80.1 mg/2.67 mL injectionSubcutaneousSQ InnovationUS FDAAvailable on request
Furoscix 80 mg/1 mL injectionSubcutaneousscPharmaceuticals Inc., a wholly ownedUS FDAAvailable on request
Furoscix 80 mg/10 mL injectionSubcutaneousscPharmaceuticals Inc., a wholly ownedUS FDAAvailable on request
Furosemide 10 mg/1 mL injectionIntravenousGeneric name—US FDAAvailable on request
Furosemide 1000 mg/100 mL injectionIntramuscular, intravenousGeneric name—US FDAAvailable on request
Furosemide 500 mg/50 mL injectionIntramuscular, intravenousGeneric name—US FDAAvailable on request

Brands by market

3 brand names across 1 markets.

Brand names by country

Manufacturers

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 1 July 1966Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Furosemide in public data. This is not a list of approved uses, see the clinical information.

Questions and answers

Is Furosemide available for export from India?

Yes, on request. MedsAcross lists 21 presentations of Furosemide and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Furosemide have?

The catalogue lists 3 brand names for Furosemide, including Furoscix, Lasix, Lasix Onyu.

Is Furosemide approved by the US FDA?

Yes. The US FDA first approved Furosemide on 1 July 1966, according to Drugs@FDA.

Is Furosemide authorised in the European Union?

Yes. Furosemide has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.

Does Furosemide need cold chain shipping?

No listed presentation of Furosemide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Furosemide in?

Furosemide is classified under ATC code C03CA01 (Furosemide).

References

  1. Lasix prescribing information (Validus Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 30 September 2025
  2. Bopediat: European public assessment report (EPAR). European Medicines Agency. Retrieved 30 June 2026

Request Furosemide for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.